Clinical Trial Update: A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating RC48-ADC in combination with JS001 as postoperative adjuvant therapy for upper tract urothelial carcinoma is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma

Drugs mentioned

• JS001 (PD-1 inhibitor)
• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: Jinling Hospital, China | Conditions: Carcinoma, Upper Tract Urothelial Carcinoma | Phase 2 | Status: RECRUITING